Comparative Pharmacology
Head-to-head clinical analysis: VIIBRYD versus VILAZODONE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIIBRYD versus VILAZODONE HYDROCHLORIDE.
VIIBRYD vs VILAZODONE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vilazodone is a selective serotonin reuptake inhibitor (SSRI) and a partial agonist at serotonin 5-HT1A receptors. It increases serotonin levels in the synaptic cleft by inhibiting its reuptake, and the 5-HT1A partial agonism may enhance serotonergic transmission and reduce side effects like sexual dysfunction.
Vilazodone is a selective serotonin reuptake inhibitor (SSRI) and a partial agonist of the 5-HT1A receptor. It increases serotonin levels in the synaptic cleft by inhibiting its reuptake, and the 5-HT1A partial agonism may enhance serotonergic neurotransmission.
10 mg orally once daily for 7 days, then 20 mg once daily for 7 days, then 40 mg once daily; target dose 40 mg once daily. Maximum dose 40 mg once daily.
40 mg orally once daily initially, may increase to 20 mg twice daily or 40 mg once daily; maximum 40 mg/day.
None Documented
None Documented
Terminal elimination half-life of vilazodone is approximately 25 hours (range 22-30 hours). Steady state is achieved within 3-4 days. The half-life supports once-daily dosing.
Terminal elimination half-life is approximately 25 hours (range 20–30 hours), supporting once-daily dosing. Steady-state is achieved within 4–5 days.
Approximately 95% of the dose is excreted in feces (as unchanged drug and metabolites) and <1% in urine as unchanged drug. Renal elimination accounts for <3% of the dose as the active metabolite.
Primarily hepatic metabolism via CYP3A4, with approximately 1% excreted unchanged in urine. Up to 60% of metabolites are excreted in urine and 20% in feces.
Category C
Category A/B
Serotonin Partial Agonist/Reuptake Inhibitor
Serotonin Partial Agonist and Reuptake Inhibitor (SPARI)